Skip to content

13F-HR filed by TCG Crossover Management, LLC

TCG Crossover Management, LLC filed this 13F-HR for the quarter ended 2025-09-30, filed 2025-11-17, with 40 holding rows worth $2,032,902,053.

Accession
0001214659-25-016751
Filed
2025-11-17
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2025

A holdings report, 40 entries on the cover page, a total value of $2,032,902,053 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,032,902,053 with VALUE read as dollars as filed, 13F file number 028-22283. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ABIVAX SA-00370M103SPONSORED ADS7,111,596$603,774,500dollars as filed
CG ONCOLOGY INC156944100COMMON STOCK3,670,206$147,835,898dollars as filed
COGENT BIOSCIENCES INC19240Q201COM6,798,162$97,621,606dollars as filed
AMYLYX PHARMACEUTICALS INC03237H101COM6,243,812$84,853,405dollars as filed
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS3,136,480$76,059,640dollars as filed
TANGO THERAPEUTICS INC87583X109COM8,536,196$71,704,046dollars as filed
OCULAR THERAPEUTIX INC67576A100COM6,117,232$71,510,442dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM1,676,624$65,975,154dollars as filed
Tourmaline Bio Inc89157D105Common Stock1,311,783$62,742,581dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock4,615,144$58,381,572dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM1,430,041$57,401,846dollars as filed
EYEPOINT INC COM NEW30233G209Stock3,572,335$50,870,050dollars as filed
FULCRUM THERAPEUTICS INC359616109COMMON STOCK5,250,000$48,300,000dollars as filed
SAVARA INC805111101COM12,362,205$44,133,072dollars as filed
RAPT THERAPEUTICS INC75382E208COM NEW1,636,275$42,199,532dollars as filed
TYRA BIOSCIENCES INC90240B106COMMON STOCK2,898,103$40,544,461dollars as filed
UPSTREAM BIO INC91678A107COMMON STOCK2,117,103$39,822,707dollars as filed
LIQUIDIA CORPORATION COM NEW53635D202Stock1,710,084$38,887,310dollars as filed
DISC MEDICINE INC COM254604101Stock465,257$30,744,183dollars as filed
STRUCTURE THERAPEUTICS INC COMP86366E106EQUITY1,063,000$29,764,000dollars as filed
XENCOR INC98401F105COMMON STOCK2,452,138$28,763,579dollars as filed
LB PHARMACEUTICALS INC50180M108COMMON STOCK1,745,016$27,553,803dollars as filed
REVOLUTION MEDICINES INC COM76155X100Stock436,473$20,383,289dollars as filed
ASTRIA THERAPEUTICS INC COM04635X102Stock2,761,861$20,106,348dollars as filed
KORRO BIO INC500946108COMMON STOCK416,301$19,936,655dollars as filed
KODIAK SCIENCES INC50015M109COM1,145,538$18,752,457dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW1,100,582$18,445,754dollars as filed
SILENCE THERAPEUTICS PLC82686Q101ADS3,033,560$15,744,176dollars as filed
UROGEN PHARMA LTDM96088105COMMON STOCK717,347$14,311,073dollars as filed
ARVINAS INC04335A105COM1,617,365$13,779,950dollars as filed
MONOPAR THERAPEUTICS INC61023L207COMMON STOCK153,000$12,495,510dollars as filed
MBX BIOSCIENCES INC COM55287L101Stock650,000$11,375,000dollars as filed
VISTAGEN THERAPEUTICS INC92840H400COM2,676,580$9,501,859dollars as filed
RELAY THERAPEUTICS INC COM75943R102Stock1,810,351$9,450,032dollars as filed
ADVERUM BIOTECHNOLOGIES INC00773U207COM NEW1,668,174$7,556,828dollars as filed
AVALO THERAPEUTICS INC05338F306COMMON STOCK483,000$6,138,930dollars as filed
ADC THERAPEUTICS SAH0036K147COMMON STOCK1,390,175$5,560,700dollars as filed
PEPGEN INC COM713317105Stock1,200,000$5,544,000dollars as filed
ENTRADA THERAPEUTICS INC COM29384C108Stock584,955$3,392,739dollars as filed
Ventyx Biosciences Inc92332V107Common Stock316,195$983,366dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001214659-25-016751this filing2025-11-17acceptance time not in the bulk data set